Nifekalant is a fast-acting Class III antiarrhythmic intravenous medication mainly approved in Japan (under the brand name Shinbit) to treat life-threatening heart rhythm disorders, including sustained ventricular tachycardia and ventricular fibrillation. It works as a selective potassium channel blocker to stabilize electrical activity in the heart. Its therapeutic use is listed as antiarrhythmics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include nifekalantum and nifekalant. Its PubChem CID is 4486.
Nifekalant
| CAS No | 130636-43-0 |
|---|---|
| Molecular Formula | C19H27N5O5 |
| Molecular Weight | 405.40 g/mol |
| Synonyms | 6-[2-[2-hydroxyethyl-[3-(4-nitrophenyl)propyl]amino]ethylamino]-1,3-dimethylpyrimidine-2,4-dione |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Nifekalant is a fast-acting Class III antiarrhythmic intravenous medication mainly approved in Japan (under the brand name Shinbit) to treat life-threatening heart rhythm disorders, including sustained ventricular tachycardia and ventricular fibrillation.
The listed CAS number is 130636-43-0.
The listed molecular formula is C19H27N5O5.
The listed molecular weight is 405.40 g/mol.
6-[2-[2-hydroxyethyl-[3-(4-nitrophenyl)propyl]amino]ethylamino]-1,3-dimethylpyrimidine-2,4-dione.
The source lists nifekalantum and nifekalant.